Mirvetuximab Combos for Platinum-resistant Ovarian Cancer Showing Promise in Trial Updates

Mirvetuximab Combos for Platinum-resistant Ovarian Cancer Showing Promise in Trial Updates
Combining Immunogen's mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety profile in patients with platinum-resistant ovarian cancer, according to data from a Phase 1/2 clinical trial. In addition, initial data from a Phase 1 trial also indicates that adding mirvetuximab to gemcitabine has acceptable safety and favorable anti-tumor activity for folate receptor alpha (FRα)-positive, and recurrent epithelial ovarian, endometrial, or triple-negative breast cancers. These updates will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31–June 4 in Chicago. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate targeting folate receptor alpha, a protein expressed at the surface of many ovarian cancers, as well as other types of solid tumors. It is a hybrid molecule where an anti-FRα antibody is linked to a potent tumor-killing agent, DM4. The Phase 1/2 trial (NCT02606305), called FORWARD II, is addressing the safety and preliminary efficacy of different combination regimens of mirvetuximab soravtansine plus chemotherapy, for patients with FRα-positive advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube tumors. The study is still recruiting at sites in the U.S., Canada, and Europe. Updated trial data for the mirvetuximab-Avastin combination will be presented at ASCO by David M. O’Malley, MD, from the Ohio State University College of Medicine, in the poster "Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findin
Subscribe or to access all post and page content.